


SARS-CoV-2

COVID-19 Alpha Variant Pseudovirus Neutralizing Antibody Assay (Luciferase)


Catalog # DE0004 Size 1 Kit

Applications




Neutralization

SARS-CoV-2 alpha variant spike pseudovirus expressing luciferase is treated with humanized monoclonal antibody 7F7 and LALAPG 7F7, and then added into 293T-ACE cells.



Neutralization

RBD-binding IgG responses in mouse sera collected 35 days and 42 days after immunization with 5 ug or 20 ug COVID-19 RBD SAM LNP no adjuvant (ppopV0) and 5 ug or 20 ug COVID-19 RBD SAM plus adjuvant (ppopV1).



In vivo Neutralization

Hamsters received 2 doses of humanized monoclonal antibody 7F7 and then were infected with SARS-CoV-2 Alpha Variant Pseudovirus Expressing Luciferase (Cat # U0402).

Specification



Product Information

Product Description	COVID-19 Alpha Variant Pseudovirus Neutralizing Antibody Assay (Luciferase) provides a highly se nsitive and quantitative measurement of neutralizing antibodies.
Supplied Product	Kit content:
oupplied i Toddet	1 kit is sufficient for 100 assays in 24 well plates
	1. 293T-hACE2 cell, 2x10 ⁶ cells/vial, FBS with 10% DMSO
	2. SARS-CoV-2 Alpha Variant Pseudovirus Expressing Luciferase
	2. Of the Cov 27 tipital variation coddovinds Expressing Education
Materials Required But	1. SARS-CoV-2 Monoclonal Antibody, Cat# MAB22854-M07, Abnova
NOT Supplied	2. ZymeFree™ Enzyme Free Cell Dissociation Reagent,
	Cat# TCL028-100ML, HIMEDIA
	3. DMEM culture medium containing 10% FBS (complete medium)
	4. Luciferase Assay System, Cat# E1500, Promega
	a. Luciferase Assay Substrate (lyophilized)
	b. Luciferase Assay Buffer
	c. Luciferase Cell Culture Lysis Reagent, 5X
	5. TC-Treated 24 Well Plates, Cat# 3524, Corning
	6. OptiPlate™-96, Cat# 6005290, PerkinElmer
Variant	B.1.1.7
Suitable Sample	1. Immunized Serum
	2. Infected Serum
	3. Neutralizing Antibodies
	4. Peptide Inhibitors or Proteins
	5. Compounds Targeting Spike Induced Cell Fusion
Sample Volume	10-50 uL (please check sample source)
Detection Method	Luciferase Activity
Technology	<u>Pseudovirus</u>
Regulatory Status	For research use only (RUO)
Storage Instruction	293T-hACE2 cell Store at liquid nitrogen.
-	Pseudovirus Store at -80°C.
	Aliquot to avoid repeated freezing and thawing.

Applications

Neutralization

SARS-CoV-2 alpha variant spike pseudovirus expressing luciferase is treated with humanized monoclonal antibody 7F7 and LALAPG 7F7, and then added into 293T-ACE cells.

Neutralization

RBD-binding lgG responses in mouse sera collected 35 days and 42 days after immunization with 5 ug or 20 ug COVID-19 RBD SAM LNP no adjuvant (ppopV0) and 5 ug or 20 ug COVID-19 RBD SAM plus adjuvant (ppopV1).



Product Information

In vivo Neutralization

Hamsters received 2 doses of humanized monoclonal antibody 7F7 and then were infected with SARS-CoV-2 Alpha Variant Pseudovirus Expressing Luciferase (Cat # U0402).